SG10201913598TA - Production of recombinant lubricin - Google Patents

Production of recombinant lubricin

Info

Publication number
SG10201913598TA
SG10201913598TA SG10201913598TA SG10201913598TA SG10201913598TA SG 10201913598T A SG10201913598T A SG 10201913598TA SG 10201913598T A SG10201913598T A SG 10201913598TA SG 10201913598T A SG10201913598T A SG 10201913598TA SG 10201913598T A SG10201913598T A SG 10201913598TA
Authority
SG
Singapore
Prior art keywords
production
recombinant lubricin
lubricin
recombinant
Prior art date
Application number
SG10201913598TA
Other languages
English (en)
Inventor
Tannin Schmidt
Gregory Jay
Original Assignee
Lubris Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris Llc filed Critical Lubris Llc
Publication of SG10201913598TA publication Critical patent/SG10201913598TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725Proteoglycans, e.g. aggreccan
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201913598TA 2013-10-22 2014-10-22 Production of recombinant lubricin SG10201913598TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361894366P 2013-10-22 2013-10-22

Publications (1)

Publication Number Publication Date
SG10201913598TA true SG10201913598TA (en) 2020-02-27

Family

ID=52993344

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913598TA SG10201913598TA (en) 2013-10-22 2014-10-22 Production of recombinant lubricin
SG11201603151VA SG11201603151VA (en) 2013-10-22 2014-10-22 Production of recombinant lubricin

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201603151VA SG11201603151VA (en) 2013-10-22 2014-10-22 Production of recombinant lubricin

Country Status (22)

Country Link
US (5) US9982027B2 (es)
EP (2) EP3971203A1 (es)
JP (2) JP6669649B2 (es)
KR (1) KR102488928B1 (es)
CN (1) CN105899527A (es)
AU (2) AU2014340080B2 (es)
BR (1) BR112016008923A2 (es)
CA (1) CA2927949A1 (es)
CY (1) CY1124861T1 (es)
DK (1) DK3060577T3 (es)
ES (1) ES2891331T3 (es)
HR (1) HRP20211497T1 (es)
HU (1) HUE056397T2 (es)
IL (2) IL245236B (es)
LT (1) LT3060577T (es)
MX (2) MX2016005302A (es)
PL (1) PL3060577T3 (es)
PT (1) PT3060577T (es)
RU (1) RU2758115C2 (es)
SG (2) SG10201913598TA (es)
SI (1) SI3060577T1 (es)
WO (2) WO2015060935A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2762989C (en) 2009-05-22 2021-04-13 Benjamin Sullivan Prg4 for treatment of oral cavity boundary lubrication disorders
EP2948553B1 (en) * 2013-01-25 2020-04-01 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP4062924A1 (en) 2013-11-26 2022-09-28 Lubris LLC Compositions and methods for inhibiting intercellular interactions
ES2808199T3 (es) 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
HUE056409T2 (hu) * 2015-05-19 2022-02-28 Lubris Llc PRG4 alkalmazása dinamikus látásélesség és magasabb rendû aberrációk javítására
EP3563894B1 (en) 2018-05-04 2021-12-22 Boehringer Ingelheim International GmbH Nebulizer and container
CN109055426B (zh) * 2018-08-06 2021-06-25 智享生物(苏州)有限公司 一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
CN114173805A (zh) * 2019-06-03 2022-03-11 卢布里斯有限责任公司 Prg4治疗癌症的用途
JP2023515504A (ja) 2020-02-24 2023-04-13 ノバルティス アーゲー 組み換え産生されたポリペプチドの精製
WO2023212598A1 (en) 2022-04-27 2023-11-02 Lubris Llc Methods of making polymer films
CN115154667A (zh) * 2022-06-27 2022-10-11 天津大学 一种基于重组润滑素蛋白修饰的胶原蛋白基质的制备方法
CN115177790A (zh) * 2022-06-27 2022-10-14 天津大学 透明质酸和润滑素蛋白协同修饰胶原蛋白基质的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000517188A (ja) * 1996-08-30 2000-12-26 ライフ テクノロジーズ,インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6530956B1 (en) * 1998-09-10 2003-03-11 Kevin A. Mansmann Resorbable scaffolds to promote cartilage regeneration
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
TW200307011A (en) 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
CN102924584A (zh) 2003-08-14 2013-02-13 惠氏公司 重组润滑素分子及其用途
EP2292754B1 (en) 2003-10-24 2012-12-26 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
US20090155200A1 (en) 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
US20080287369A1 (en) 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
EP1827478A4 (en) 2004-12-03 2009-08-05 Mucosal Therapeutics Llc METHODS OF TREATING JOINED OR SICK JOINTS
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー 1日1回投与用トラゾドン組成物
WO2008023247A2 (en) * 2006-08-23 2008-02-28 Selexis S.A. Matrix attachment regions (mars) for increasing transcription and uses thereof
JP5660561B2 (ja) 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド ジョイント部の潤滑に関するグリセロリン脂質の使用
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
JP5508398B2 (ja) 2008-05-07 2014-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の表面潤滑の治療的補充及び強化
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
WO2010083239A2 (en) 2009-01-13 2010-07-22 Truitt Edward R Iii Therapeutic modulation of vaginal epithelium boundary lubrication
CA2762989C (en) 2009-05-22 2021-04-13 Benjamin Sullivan Prg4 for treatment of oral cavity boundary lubrication disorders
US9107885B2 (en) 2009-08-13 2015-08-18 Lubris Llc PRG4 treatment for interstitial cystitis
KR20120099376A (ko) 2009-09-18 2012-09-10 셀렉시스 에스. 에이. 강화된 전이 유전자 발현과 공정 방법 및 그 산물
ES2627103T3 (es) 2010-01-19 2017-07-26 Lubris Llc Composiciones de cuidado bucal y métodos
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP4062924A1 (en) 2013-11-26 2022-09-28 Lubris LLC Compositions and methods for inhibiting intercellular interactions
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
ES2808199T3 (es) 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
HUE056409T2 (hu) 2015-05-19 2022-02-28 Lubris Llc PRG4 alkalmazása dinamikus látásélesség és magasabb rendû aberrációk javítására
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
RU2758115C2 (ru) 2021-10-26
JP2020039348A (ja) 2020-03-19
US9982027B2 (en) 2018-05-29
PL3060577T3 (pl) 2022-01-24
PT3060577T (pt) 2021-10-01
EP3060577A4 (en) 2017-05-17
AU2014340080A1 (en) 2016-06-02
KR20160086843A (ko) 2016-07-20
US20160304572A1 (en) 2016-10-20
JP6669649B2 (ja) 2020-03-18
RU2016119532A (ru) 2017-11-28
IL245236A0 (en) 2016-06-30
EP3971203A1 (en) 2022-03-23
DK3060577T3 (da) 2021-10-04
WO2015060935A1 (en) 2015-04-30
JP6970164B2 (ja) 2021-11-24
MX2021003243A (es) 2021-05-12
EP3060577B1 (en) 2021-07-07
AU2014340080B2 (en) 2018-12-06
US20230234999A1 (en) 2023-07-27
HUE056397T2 (hu) 2022-02-28
AU2019201478B2 (en) 2021-07-08
CY1124861T1 (el) 2022-11-25
RU2016119532A3 (es) 2018-05-16
US10723773B2 (en) 2020-07-28
US10125180B2 (en) 2018-11-13
IL283447A (en) 2021-07-29
ES2891331T3 (es) 2022-01-27
US20210130427A1 (en) 2021-05-06
CA2927949A1 (en) 2015-04-30
SG11201603151VA (en) 2016-05-30
US20190270783A1 (en) 2019-09-05
IL245236B (en) 2021-12-01
SI3060577T1 (sl) 2021-12-31
US11485764B2 (en) 2022-11-01
JP2016535590A (ja) 2016-11-17
LT3060577T (lt) 2021-12-27
EP3060577A1 (en) 2016-08-31
CN105899527A (zh) 2016-08-24
AU2019201478A1 (en) 2019-03-28
WO2015061488A1 (en) 2015-04-30
KR102488928B1 (ko) 2023-01-13
US20160250286A1 (en) 2016-09-01
MX2016005302A (es) 2017-02-15
BR112016008923A2 (pt) 2017-09-19
HRP20211497T1 (hr) 2021-12-24

Similar Documents

Publication Publication Date Title
IL283447A (en) Production of recombinant lubricin
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
SG11201506876XA (en) Modification of polypeptides
GB2520496B (en) Production of graphene oxide
RS58097B1 (sr) Terapeutske primene empagliflozina
PL3041945T3 (pl) Wytwarzanie galakto-oligosacharydów
HK1220492A1 (zh) 重組多肽生產
GB201318700D0 (en) Manufacture of microneedles
GB201707235D0 (en) Production of butanol
PL3071575T3 (pl) Wytwarzanie normorfinanów
HK1198422A1 (en) Novel uses of colossolactones
GB201304608D0 (en) BenTime of Yisrael operable arrangement
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling
GB201318284D0 (en) Construction of surfaces
GB201303595D0 (en) Production of butanol